Literature DB >> 33105471

Initiation of Antiretroviral Therapy during Primary HIV Infection: Effects on the Latent HIV Reservoir, Including on Analytic Treatment Interruptions.

Eva M Shelton1, Daniel B Reeves2, Rachel A Bender Ignacio3.   

Abstract

Antiretroviral therapy (ART) inhibits HIV replication but does not eradicate the latent reservoir. The previous research suggests that earlier ART initiation provides benefit on limiting reservoir size, but timing and extent of this effect remain unclear. Analytic treatment interruption (ATI) may be used to demonstrate HIV remission, but whether early ART also improves likelihood or duration of even temporary virologic remission is unclear. This review seeks to answer both questions. We performed a systematic review and analysis following Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines and included 21 interventional or observational studies with sufficient HIV reservoir outcomes. We also aggregated reservoir outcomes and transformed data into approximate measurements of total HIV DNA per million peripheral blood mononuclear cells and analyzed the correlation between timing of ART initiation and reservoir size. People living with HIV who initiate ART in primary infection maintain smaller reservoirs on suppressive ART than those who initiate treatment during chronic infection. The reduction of reservoir is most pronounced when ART is started within 2 weeks of HIV acquisition. Across studies, we found a moderately strong association between longer time to ART initiation and reservoir size, which was strongest when measured after 1 year on ART (Pearson's r = 0.69, p = 0.0003). After ATI, larger pre-ATI reservoir size predicts shorter time to viral rebound. Early ART may also facilitate long-term control of viremia. Although achieving sustained HIV remission will require further interventions, initiating ART very early in infection could limit the extent of the reservoir and also lead to post-ATI control in rare cases.

Entities:  

Keywords:  Primary HIV; Acute HIV; HIV reservoir; Antiretroviral therapy; Analytic treatment interruption (ATI)

Year:  2020        PMID: 33105471      PMCID: PMC7987773          DOI: 10.24875/AIDSRev.20000001

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  58 in total

1.  HIV-1 integration landscape during latent and active infection.

Authors:  Lillian B Cohn; Israel T Silva; Thiago Y Oliveira; Rafael A Rosales; Erica H Parrish; Gerald H Learn; Beatrice H Hahn; Julie L Czartoski; M Juliana McElrath; Clara Lehmann; Florian Klein; Marina Caskey; Bruce D Walker; Janet D Siliciano; Robert F Siliciano; Mila Jankovic; Michel C Nussenzweig
Journal:  Cell       Date:  2015-01-29       Impact factor: 41.582

2.  Unintended HIV-1 Infection During Analytical Therapy Interruption.

Authors:  Ainoa Ugarte; Yolanda Romero; Amparo Tricas; Concepcion Casado; Cecilio Lopez-Galindez; Felipe Garcia; Lorna Leal
Journal:  J Infect Dis       Date:  2020-04-27       Impact factor: 5.226

3.  Clinical and Immunologic Outcomes After Immediate or Deferred Antiretroviral Therapy Initiation During Primary Human Immunodeficiency Virus Infection: The Sabes Randomized Clinical Study.

Authors:  Javier R Lama; Rachel A Bender Ignacio; Ricardo Alfaro; Jessica Rios; Jorge Gallardo Cartagena; Rogelio Valdez; Carolyn Bain; Karin Sosa Barbarán; Manuel V Villaran; Christopher D Pilcher; Pedro Gonzales; Jorge Sanchez; Ann Duerr
Journal:  Clin Infect Dis       Date:  2021-03-15       Impact factor: 9.079

4.  Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection.

Authors:  J N Blankson; D Finzi; T C Pierson; B P Sabundayo; K Chadwick; J B Margolick; T C Quinn; R F Siliciano
Journal:  J Infect Dis       Date:  2000-11-08       Impact factor: 5.226

Review 5.  How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs?

Authors:  Jintanat Ananworanich; Karine Dubé; Nicolas Chomont
Journal:  Curr Opin HIV AIDS       Date:  2015-01       Impact factor: 4.283

6.  Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells.

Authors:  Maria J Buzon; Enrique Martin-Gayo; Florencia Pereyra; Zhengyu Ouyang; Hong Sun; Jonathan Z Li; Michael Piovoso; Amy Shaw; Judith Dalmau; Nadine Zangger; Javier Martinez-Picado; Ryan Zurakowski; Xu G Yu; Amalio Telenti; Bruce D Walker; Eric S Rosenberg; Mathias Lichterfeld
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

7.  HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.

Authors:  Cécile Goujard; Isabelle Girault; Christine Rouzioux; Camille Lécuroux; Christiane Deveau; Marie-Laure Chaix; Christine Jacomet; Amel Talamali; Jean-François Delfraissy; Alain Venet; Laurence Meyer; Martine Sinet
Journal:  Antivir Ther       Date:  2012-08-06

8.  Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption.

Authors:  Viktor von Wyl; Sara Gianella; Marek Fischer; Barbara Niederoest; Herbert Kuster; Manuel Battegay; Enos Bernasconi; Matthias Cavassini; Andri Rauch; Bernard Hirschel; Pietro Vernazza; Rainer Weber; Beda Joos; Huldrych F Günthard
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

9.  Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation.

Authors:  Rajesh T Gandhi; Deborah K McMahon; Ronald J Bosch; Christina M Lalama; Joshua C Cyktor; Bernard J Macatangay; Charles R Rinaldo; Sharon A Riddler; Evelyn Hogg; Catherine Godfrey; Ann C Collier; Joseph J Eron; John W Mellors
Journal:  PLoS Pathog       Date:  2017-04-20       Impact factor: 6.823

10.  Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection.

Authors:  Donn J Colby; Lydie Trautmann; Suteeraporn Pinyakorn; Louise Leyre; Amélie Pagliuzza; Eugène Kroon; Morgane Rolland; Hiroshi Takata; Supranee Buranapraditkun; Jintana Intasan; Nitiya Chomchey; Roshell Muir; Elias K Haddad; Sodsai Tovanabutra; Sasiwimol Ubolyam; Diane L Bolton; Brandie A Fullmer; Robert J Gorelick; Lawrence Fox; Trevor A Crowell; Rapee Trichavaroj; Robert O'Connell; Nicolas Chomont; Jerome H Kim; Nelson L Michael; Merlin L Robb; Nittaya Phanuphak; Jintanat Ananworanich
Journal:  Nat Med       Date:  2018-06-11       Impact factor: 53.440

View more
  2 in total

1.  Acute HIV-1 infection viremia associate with rebound upon treatment interruption.

Authors:  Thembi Mdluli; Yifan Li; Suteeraporn Pinyakorn; Daniel B Reeves; E Fabian Cardozo-Ojeda; Adam Yates; Jintana Intasan; Somporn Tipsuk; Nittaya Phanuphak; Carlo Sacdalan; Donn J Colby; Eugène Kroon; Trevor A Crowell; Rasmi Thomas; Merlin L Robb; Jintanat Ananworanich; Mark de Souza; Praphan Phanuphak; Daniel J Stieh; Frank L Tomaka; Lydie Trautmann; Julie A Ake; Denise C Hsu; Leilani V Francisco; Sandhya Vasan; Morgane Rolland
Journal:  Med (N Y)       Date:  2022-07-22

2.  Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1.

Authors:  Ashley N Nelson; Maria Dennis; Jesse F Mangold; Katherine Li; Pooja T Saha; Kenneth Cronin; Kaitlyn A Cross; Amit Kumar; Riley J Mangan; George M Shaw; Katharine J Bar; Barton Haynes; Anthony M Moody; S Munir Alam; Justin Pollara; Michael G Hudgens; Koen K A Van Rompay; Kristina De Paris; Sallie R Permar
Journal:  NPJ Vaccines       Date:  2022-07-30       Impact factor: 9.399

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.